“With the initiation of our Phase 3 trial of A4250 in progressive familial intrahepatic cholestasis (PFIC), Albireo has entered the next stage of growth, and we must continue to build the company for the future,” said Ron Cooper, President and Chief Executive Officer of Albireo. “Jason’s extensive legal and compliance leadership experience with both development and commercial orphan products will be a tremendous asset to the company. We are pleased to welcome him to Albireo.”
Mr. Duncan joins Albireo with more than 15 years of legal and compliance experience in the pharmaceutical industry. He most recently served as General Counsel at
“I am excited to join Albireo at this pivotal moment in the company’s history,” Mr. Duncan said. “I look forward to supporting the company’s growth and long-term success, and to working with Albireo’s talented team on bringing potentially transformative medicines to patients and their families.”
Earlier in his career, Mr. Duncan practiced at
Albireo Pharma is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and gastrointestinal diseases and disorders. Albireo’s lead product candidate, A4250, is being developed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in its initial target indication, progressive familial intrahepatic cholestasis. Albireo’s clinical pipeline also includes two Phase 2 product candidates. Albireo’s elobixibat, approved in Japan for the treatment of chronic constipation, is the first ileal bile acid transporter (IBAT) inhibitor approved anywhere in the world. Albireo was spun out from AstraZeneca in 2008.
Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary is located in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.
Source: Albireo Pharma, Inc.